BioCentury | Jan 12, 2021
Deals

Jan. 11 Quick Takes: Inmagene gains options to four Chi-Med immunology programs; plus Zai-Turning Point, Mirati-Resolution, GSK-Eligo, Biogen-Apple, Adaptive-AZ and more

...Group will gain exclusive rights from Aadi Bioscience Inc. to develop and commercialize mTOR inhibitor ABI-009...
...up to $271 million in upfront and milestone payments, plus tiered royalties. Aadi is developing ABI-009...
BioCentury | Nov 10, 2020
Finance

Nov. 9 Quick Takes: Biogen sheds $14B in value; plus Ambrx’s 200M round, Decibel’s series D and more

...69% on Friday based on a readout from a Phase II extension study of vebicorvir (ABI-H0731...
BioCentury | Jul 20, 2020
Deals

Putting cash to work, BeiGene taps Assembly’s HBV program for first non-oncology deal

...which the companies will split costs evenly. Included in the deal are ABI-H0731, ABI-H2158 and ABI-H3733...
...added $5.28 to $253.95. Targets PARP-1 - Poly(ADP-ribose) polymerase-1 PARP-2 - Poly(ADP-ribose) polymerase-2 Paul Bonanos, Associate Editor ABI-H0731 ABI-H2158 ABI-H3733 Assembly...
BioCentury | Jun 23, 2020
Product Development

June 22 Quick Takes: Invitae acquiring ArcherDX; plus lymphoma approval for Karyopharm, Merck, Nabriva, Myovant, Assembly-AbbVie, Genentech and more

...ABI-M201, which is in Phase Ib testing for ulcerative colitis, and preclinical Crohn’s disease program ABI-M301...
...Phosphatase and tensin homolog deleted on chromosome ten BioCentury Staff PCV-15 (V114) Contepo, fosfomycin (Zolyd, ZTI-01) Relumina (relugolix, TAK-385) ABI-M201 ABI-M301 ipatasertib...
BioCentury | May 19, 2020
Emerging Company Profile

Helmed by OrbiMed’s Wang, Inmagene debuts with Phase II autoimmune program

Inmagene emerged from stealth last week with plans to expand the biologics markets in China, starting with a Phase II psoriasis program it in-licensed from Swedish biotech Affibody. The candidate, IMG-020, is expected to be...
BioCentury | Mar 26, 2020
Regulation

China’s NMPA suspends Abraxane imports after U.S. inspection

...to $78.80 in Hong Kong Wednesday; BMS’s stock was largely unchanged. Hongjiang Li, Staff Writer Abraxane, nab-paclitaxel (ABI-007) BeiGene...
BioCentury | Mar 16, 2020
Product Development

COVID-19 Roundup: Trial starts for Moderna, Sanofi-Regeneron and BioNTech; plus Thermo Fisher, Roche and VIB

...NYSE:TMO) to detect nucleic acids from SARS-CoV-2. The test is designed to run on the Applied Biosystems...
BioCentury | Jan 23, 2020
Politics & Policy

MNCs lead price cuts in China’s second round of centralized procurement

...to the program this year, according to Bernstein’s Shan He. Hongjiang Li, Staff Writer Zocor, simvastatin Abraxane, nab-paclitaxel (ABI-007) Novartis...
BioCentury | Oct 25, 2019
Clinical News

Galapagos optimistic on filgotinib beyond RA, despite two misses

...of failures in cutaneous lupus and Sjögren syndrome. “I’m personally excited about these results,” Walid Abi-Saab...
...studies. Sundy is SVP, clinical research, inflammation and respiratory therapeutics at Gilead Sciences Inc. (NASDAQ:GILD). Abi-Saab...
BioCentury | Sep 9, 2019
Company News

BeiGene pushes back on short seller report

...by the firm. The company regained its losses two weeks later. Hongjiang Li, Staff Writer Abraxane, nab-paclitaxel (ABI-007) Revlimid...
Items per page:
1 - 10 of 1090
BioCentury | Jan 12, 2021
Deals

Jan. 11 Quick Takes: Inmagene gains options to four Chi-Med immunology programs; plus Zai-Turning Point, Mirati-Resolution, GSK-Eligo, Biogen-Apple, Adaptive-AZ and more

...Group will gain exclusive rights from Aadi Bioscience Inc. to develop and commercialize mTOR inhibitor ABI-009...
...up to $271 million in upfront and milestone payments, plus tiered royalties. Aadi is developing ABI-009...
BioCentury | Nov 10, 2020
Finance

Nov. 9 Quick Takes: Biogen sheds $14B in value; plus Ambrx’s 200M round, Decibel’s series D and more

...69% on Friday based on a readout from a Phase II extension study of vebicorvir (ABI-H0731...
BioCentury | Jul 20, 2020
Deals

Putting cash to work, BeiGene taps Assembly’s HBV program for first non-oncology deal

...which the companies will split costs evenly. Included in the deal are ABI-H0731, ABI-H2158 and ABI-H3733...
...added $5.28 to $253.95. Targets PARP-1 - Poly(ADP-ribose) polymerase-1 PARP-2 - Poly(ADP-ribose) polymerase-2 Paul Bonanos, Associate Editor ABI-H0731 ABI-H2158 ABI-H3733 Assembly...
BioCentury | Jun 23, 2020
Product Development

June 22 Quick Takes: Invitae acquiring ArcherDX; plus lymphoma approval for Karyopharm, Merck, Nabriva, Myovant, Assembly-AbbVie, Genentech and more

...ABI-M201, which is in Phase Ib testing for ulcerative colitis, and preclinical Crohn’s disease program ABI-M301...
...Phosphatase and tensin homolog deleted on chromosome ten BioCentury Staff PCV-15 (V114) Contepo, fosfomycin (Zolyd, ZTI-01) Relumina (relugolix, TAK-385) ABI-M201 ABI-M301 ipatasertib...
BioCentury | May 19, 2020
Emerging Company Profile

Helmed by OrbiMed’s Wang, Inmagene debuts with Phase II autoimmune program

Inmagene emerged from stealth last week with plans to expand the biologics markets in China, starting with a Phase II psoriasis program it in-licensed from Swedish biotech Affibody. The candidate, IMG-020, is expected to be...
BioCentury | Mar 26, 2020
Regulation

China’s NMPA suspends Abraxane imports after U.S. inspection

...to $78.80 in Hong Kong Wednesday; BMS’s stock was largely unchanged. Hongjiang Li, Staff Writer Abraxane, nab-paclitaxel (ABI-007) BeiGene...
BioCentury | Mar 16, 2020
Product Development

COVID-19 Roundup: Trial starts for Moderna, Sanofi-Regeneron and BioNTech; plus Thermo Fisher, Roche and VIB

...NYSE:TMO) to detect nucleic acids from SARS-CoV-2. The test is designed to run on the Applied Biosystems...
BioCentury | Jan 23, 2020
Politics & Policy

MNCs lead price cuts in China’s second round of centralized procurement

...to the program this year, according to Bernstein’s Shan He. Hongjiang Li, Staff Writer Zocor, simvastatin Abraxane, nab-paclitaxel (ABI-007) Novartis...
BioCentury | Oct 25, 2019
Clinical News

Galapagos optimistic on filgotinib beyond RA, despite two misses

...of failures in cutaneous lupus and Sjögren syndrome. “I’m personally excited about these results,” Walid Abi-Saab...
...studies. Sundy is SVP, clinical research, inflammation and respiratory therapeutics at Gilead Sciences Inc. (NASDAQ:GILD). Abi-Saab...
BioCentury | Sep 9, 2019
Company News

BeiGene pushes back on short seller report

...by the firm. The company regained its losses two weeks later. Hongjiang Li, Staff Writer Abraxane, nab-paclitaxel (ABI-007) Revlimid...
Items per page:
1 - 10 of 1090